INDV
Get informed when a big investor buys or sells
+ FollowOvervalued by 103.1% based on the discounted cash flow analysis.
| Market cap | $4.69 Billion |
|---|---|
| Enterprise Value | $4.58 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.68 |
| Beta | 1.2 |
| Outstanding Shares | 125,352,000 |
| P/E Ratio | 18.79 |
|---|---|
| PEG | 21.02 |
| Price to Sales | 3.85 |
| Price to Book Ratio | -19.24 |
| Enterprise Value to Revenue | 3.55 |
| Enterprise Value to EBIT | 13.51 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.44 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8729▲ 83.26% |
|---|---|
| Total Calls | 310,900▼ 85.00% |
| Total Puts | 271,400▲ 224.25% |
Holdings and activity of institutional investors.
| Ownership % | 102.18%▲ 11.73% |
|---|---|
| Total Invested | $3.89B▼ 4.00% |
| Investors Holding | 296▲ 39.00% |
No data
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...